Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 354,829,152
  • Shares Outstanding, K 2,631,873
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.69
  • Price/Sales 4.35
  • Price/Cash Flow 12.37
  • Price/Book 5.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.86
  • Number of Estimates 7
  • High Estimate 1.89
  • Low Estimate 1.85
  • Prior Year 1.97
  • Growth Rate Est. (year over year) -5.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.10 +7.80%
on 10/24/19
136.34 -0.29%
on 11/20/19
+8.24 (+6.45%)
since 10/18/19
3-Month
126.10 +7.80%
on 10/24/19
137.49 -1.13%
on 10/17/19
+5.34 (+4.09%)
since 08/20/19
52-Week
121.00 +12.35%
on 12/24/18
148.99 -8.76%
on 12/04/18
-10.51 (-7.18%)
since 11/20/18

Most Recent Stories

More News
Janssen Receives EU Marketing Authorisation for Darzalex(R)(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex(R)(daratumumab) in combination with lenalidomide...

JNJ : 135.94 (+0.83%)
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Johnson & Johnson, Boeing and PetroChina

The Zacks Analyst Blog Highlights: Alphabet, Amazon, Johnson & Johnson, Boeing and PetroChina

AMZN : 1,745.53 (-0.41%)
GOOGL : 1,301.86 (-0.82%)
JNJ : 135.94 (+0.83%)
BA : 370.91 (+1.07%)
PTR : 47.35 (+1.20%)
Johnson & Johnson Vision Announces National Availability of ACUVUE OASYS with Transitions Light Intelligent Technology in the UK

First-of-its-kind(1) contact lens delivers superior visual performance(2) with seamless adaptation to light day and night(3)

JNJ : 135.94 (+0.83%)
Top Analyst Reports for Alphabet, Amazon & Johnson & Johnson

Top Analyst Reports for Alphabet, Amazon & Johnson & Johnson

UNH : 275.56 (+0.48%)
PTR : 47.35 (+1.20%)
JNJ : 135.94 (+0.83%)
GOOGL : 1,301.86 (-0.82%)
BA : 370.91 (+1.07%)
AMZN : 1,745.53 (-0.41%)
Biosense Webster Launches a Two-pronged Initiative to Tackle the New Millennium Epidemic of Atrial Fibrillation

Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today reaffirmed its commitment to tackling this new millennium epidemic...

JNJ : 135.94 (+0.83%)
International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppression

The Janssen Pharmaceutical Companies of Johnson & Johnson announces the first consensus white paper to be published by an esteemed group of experts who have come together to launch the "Moving Fourth"...

JNJ : 135.94 (+0.83%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (RVNC , AERI , JNJ , PRGO , CTLT )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

AERI : 17.85 (-5.41%)
JNJ : 135.94 (+0.83%)
RVNC : 16.29 (+0.56%)
Scandinavian ChemoTech and its CEO Mohan Frick Participates and Presents at the Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and its CEO Mohan Frick has been selected to present its Tumour Specific Electroporation at the Emerging Medtech Summit in California, USA. An event bringing together the top strategists,...

BSX : 42.61 (-0.05%)
JNJ : 135.94 (+0.83%)
MDT : 111.79 (+0.65%)
WFC : 53.54 (-0.91%)
Janssen Leverages Wearable Technology to Reimagine Clinical Trial Design

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of the next evolution of digital clinical trial design with CHIEF-HF, the first-ever completely decentralized, mobile,...

JNJ : 135.94 (+0.83%)
PRAH : 106.90 (-0.52%)
Oklahoma judge reduces J&J order in opioid lawsuit by $107M

OKLAHOMA CITY (AP) — An Oklahoma judge who last summer ordered consumer products giant Johnson & Johnson to help address the state’s opioid crisis on Friday reduced that amount in his final order...

JNJ : 135.94 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 137.72
1st Resistance Point 136.83
Last Price 135.94
1st Support Level 134.56
2nd Support Level 133.18

See More

52-Week High 148.99
Fibonacci 61.8% 138.30
Last Price 135.94
Fibonacci 50% 134.99
Fibonacci 38.2% 131.69
52-Week Low 121.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar